Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam

被引:15
|
作者
Kaljee, Linda M. [1 ]
Pham, Van
Son, Nguyen Dinh
Hoa, Nguyen Thai
Thiem, Vu Dinh
Canh, Do Gia
Kim Thoa, Le Thi
Ali, Mohammad
Ochiai, Rion Leon
Danovaro-Holliday, M. Carolina
Acosta, Camilo J.
Stanton, Bonita
Clemens, John
机构
[1] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA
[3] Prov Prevent Med Ctr, Hue City, Thua Thien, Vietnam
[4] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[5] Ha Noi Med Univ, Hanoi, Vietnam
[6] Int Vaccine Inst, Seoul, South Korea
[7] Wayne State Univ, Sch Med, Carman & Ann Adams Dept Pediat, Detroit, MI USA
关键词
children/adolescents; enteric disease; vaccination; typhoid fever; Viet Nam;
D O I
10.1111/j.1365-3156.2006.01751.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVES To identify demand for Vi typhoid fever vaccine for school-age children; obstacles and enabling factors for vaccine delivery; and socio-behavioural factors associated with trial participation and possible predictors of future vaccine acceptance, in Hue City, Viet Nam. METHODS Pre- and post-trial surveys of randomly selected households with children aged 6-17 years. Simple multinomial logistic analyses for ratios of relative risks (RRR) and significance on trial participation by demographics and variables related to typhoid fever, vaccination, and pre-trial experiences with information and consents. Multiple logistic regressions to assess differences in participation based on child's characteristics. RESULTS As many as 62.6% of households let all school age children participate, 10.2% let some participate, and 26.8% let none of their children participate in the trial. Factors associated with all children participating included past use of healthcare facilities (RRR, 0.45; 95% CI, 0.24-0.83), knowledge of vaccines (RRR, 0.17; 95% CI, 0.03-0.86), and perceived causes of typhoid fever (RRR, 0.90; 95% CI, 0.81-0.99). Factors associated with some children participating included utilization of healthcare facilities (RRR, 0.08; 95% CI, 0.01-0.66) and perceived severity of typhoid fever (RRR, 0.64; 95% CI 0.46-0.88). Participation was associated with satisfaction regarding pre-vaccination information and consent procedures. Children and adolescents were active decision-makers. Only 14 of 461 (2.2%) respondents would not use the Vi vaccine in the future for their child(ren). CONCLUSIONS Inter-related factors contribute to participation in a clinical vaccine trial, which may differ from desire to participate in a public health campaign. Educational campaigns need to be targeted to children and adolescents, and consideration for assent procedures for minors. Obtaining informed consent may affect trial participation within a social and political system unaccustomed to these procedures.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 50 条
  • [1] Vaccine desirability during an effectiveness trial of the typhoid fever polysaccharide Vi vaccine in Kolkata, India
    Sur, Dipika
    Manna, Byomkesh
    Chakrabarty, Nandini
    Kaljee, Linda M.
    Riel, Rosemary
    Pach, Alfred
    Kanungo, Suman
    Deen, Jacqueline
    Ochiai, R. Leon
    Clemens, John
    Bhattacharya, S. K.
    HUMAN VACCINES, 2009, 5 (09): : 614 - 620
  • [2] Development of a synthetic Vi polysaccharide vaccine for typhoid fever
    Ni, Yawei
    Springer, Michael J.
    Guo, Jianhua
    Finger-Baker, Isaac
    Wilson, James P.
    Cobb, Ronald R.
    Turner, Debra
    Tizard, Ian
    VACCINE, 2017, 35 (51) : 7121 - 7126
  • [3] Use of Typhoid Vi-Polysaccharide Vaccine as a Vaccine Probe to Delineate Clinical Criteria for Typhoid Fever
    Islam, Md Taufiqul
    Im, Justin
    Ahmmed, Faisal
    Kim, Deok Ryun
    Khan, Ashraful Islam
    Zaman, Khalequ
    Ali, Mohammad
    Marks, Florian
    Qadri, Firdausi
    Kim, Jerome H.
    Clemens, John D.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2020, 103 (02): : 665 - 671
  • [4] Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever
    Giannelli, C.
    Cappelletti, E.
    Di Benedetto, R.
    Pippi, F.
    Arcuri, M.
    Di Cioccio, V.
    Martin, L. B.
    Saul, A.
    Micoli, F.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 139 : 143 - 147
  • [5] Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China
    Yang, HH
    Wu, CG
    Xie, GZ
    Gu, QW
    Wang, BR
    Wang, LY
    Wang, HF
    Ding, ZS
    Yang, Y
    Tan, WS
    Wang, WY
    Wang, XC
    Qin, M
    Wang, JH
    Tang, HA
    Jiang, XM
    Li, YH
    Wang, ML
    Zhang, SL
    Li, GL
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2001, 79 (07) : 625 - 631
  • [6] Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever
    Froeschle, James E.
    Decker, Michael D.
    VACCINE, 2010, 28 (06) : 1451 - 1453
  • [7] PROTECTIVE ACTIVITY OF VI-CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID-FEVER
    KLUGMAN, KP
    KOORNHOF, HJ
    SCHNEERSON, R
    CADOZ, M
    GILBERTSON, IT
    ROBBINS, JB
    SCHULZ, D
    ARMAND, J
    LANCET, 1987, 2 (8569): : 1165 - 1169
  • [8] Clinical profile of a typhoid Vi polysaccharide vaccine - Foreword
    Griffin, GE
    BIODRUGS, 2001, 15
  • [9] A NEW TYPHOID VACCINE COMPOSED OF THE VI CAPSULAR POLYSACCHARIDE
    PLOTKIN, SA
    BOUVERETLECAM, N
    ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (21) : 2293 - 2299
  • [10] EXPERIENCE WITH VI TYPHOID CAPSULAR POLYSACCHARIDE VACCINE IN THE UK
    ARNOLD, WSG
    HARCUS, AW
    ROBERTS, JS
    WARD, AE
    JOURNAL OF INFECTION, 1992, 25 (01) : 63 - 66